Bellevue Asset Management AG
- Land: Schweiz
Nachricht vom 04.05.2020 | 14:30
Bellevue Asset Management AG: Defensive stocks for stormy weather
EQS Group-News: Bellevue Asset Management AG
/ Key word(s): Market Report
Press release of May 4, 2020
Defensive stocks for stormy weather
The Asian healthcare market is entering another period of fast growth. Japan continues to demonstrate technology leadership in healthcare, while China is emerging as a new laboratory of healthcare system innovation in the wake of concerted action to modernize and reform its national health system. Chinese healthcare companies are particularly likely to become stronger in the aftermath of the coronavirus pandemic. Portfolio Managers Oliver Kubli and Remo Krauer from Bellevue Asset Management are focused on the most promising investment opportunities in the Asian healthcare universe.
Asia was the starting point of the global coronavirus outbreak. The Covid-19 pandemic is accelerating the adoption of digital technologies across the region's healthcare industry. During the lockdown in China, for example, Ping An Healthcare, Alibaba Health and other Chinese online healthcare providers reported a surge in virtual doctor consultations and this has given the trend towards digitization in healthcare more momentum.
Defensive qualities in times of market turmoil
BB Adamant Asia Pacific Healthcare and BB Adamant Emerging Markets Healthcare (80% Asia exposure), two of our regional strategy funds, have performed very well year to date (as of April 30), both in absolute terms and relative to the broader market. Measured in USD, the two funds have gained 11.9% and 9.7%, respectively, whereas the broad Asia-Pacific stock market has retreated by 14.4% and the broader emerging market index is down 17.1% year to date.
Healthcare's outperformance of the broader market has been particularly evident since mid-March when stocks began to recover from the steep market sell-off. A major reason for this is the increasing visibility of the generally solidly financed healthcare companies in the eyes of the investment community as well as the broader public. Meanwhile the pandemic has demonstrated quite clearly just how important a well-functioning healthcare system is. Drug developers and providers of medical technology are being viewed as solution-makers who will get us through the crisis.
Asian companies with treatments for Covid-19
Innovent Biologics is a Chinese company that is developing a monoclonal antibody drug as a vaccine for COVID-19. Takeda Pharma, a Japanese firm, and its Australian partner CSL are using a well-established technology to develop a hyperimmune immunoglobulin medicine that would boost the ability of a body's immune system to fight Covid-19. Wuxi Biologics and Samsung Biologics have state-of-the-art pharmaceutical manufacturing facilities. Dr Reddy's, a company in India, produces an old anti-malarial drug that is currently being investigated as a potential treatment for Coronavirus disease. The Japanese drug maker Chugai has initiated a clinical trial of Actemra, a drug already approved for patients with autoimmune disease, as a last line of defense against severe immune overreactions that have often led to the death of Covid-19 patients. The Asian healthcare sector is also attracting attention as a global supplier of medtech and diagnostic products, ranging from personal protective equipment to respirators and test kits. Mindray, for example, is a Chinese manufacturer of ventilators that also sells its products to customers in the US. The Malaysian company Top Glove manufactures 73 billion rubber gloves a year and is now expanding its annual capacity to 90 billion.
China - a laboratory of innovation
Chinese healthcare companies are likely to emerge from the corona crisis stronger than before. Recent developments confirm that the Chinese government is pushing in the right direction with its efforts to improve the efficiency, quality and integrative approach of the country's healthcare industry. The biomedical and medical device industries are among the 10 industries that have been prioritized in the government's "Made in China 2025" plan. Some of the policies and measures the Chinese government laid out to promote structural growth in these industries were borrowed from the German government's Industry 4.0 development plan. A basic objective of this 10-year plan is to move the country higher up the value chain. Beijing wants to increase the domestic content of core materials or processes in the designated industries to 70% by 2025.
Strategically and financially, the government is calling all the shots. It successfully introduced nationwide drug tenders and centralized drug procurement processes that have lowered the prices for generics. The resulting savings are being channeled into research and development. These investments will pay off during the coming years: In 2018, domestically developed drugs protected by patents accounted for 40% of all drugs in the Chinese market; this share is projected to stand at 65% in 2023.
Innovent, one of the stocks in our investment portfolio, is a prime example of a Chinese biotech success story. Innovent has built up a pipeline of candidates for the treatment of cancer and autoimmune, cardiovascular and other diseases. Its oncology drug Sintilimab approved in December 2018 by China's regulatory authority was the country's second domestically developed immunotherapy for patients with classic Hodgkin's lymphoma. Sintilimab also showed positive efficacy data as a combination therapy for patients with lung cancer. Wuxi Biologics, another stock in the portfolios of both funds, has become an internationally leading contract manufacturer for multinational companies and it has developed a proprietary technology platform.
Japan - the demographic laboratory
No other country has a higher percentage of citizens aged 65 or older than Japan, and that is a boon to the country's healthcare sector.
Eisai, a pharmaceuticals company, boasts the world's deepest pool of research data on Alzheimer's disease. If the US FDA gives the green light sometime this year, Eisai and its US partner Biogen could begin to market the very first drug that actually slows the progression of Alzheimer's disease. Other Japanese companies such as Astellas Pharma, Chugai Pharma and Daiichi Sankyo are active in oncology, gene therapy or rare hereditary diseases.
Medical technology is another field in which Japanese companies are leaders, with products ranging from stents and catheters to medical imaging systems. Olympus, one of the largest positions in our Asia Pacific Healthcare Fund, has undergone a strategic and financial transformation over the past several years. The company is a global technology leader in endoscopy with a world market share of 70%. Thanks to its latest generation of endoscopy solutions, Olympus will generate high growth in the coming years. This will be fueled by innovations such as a platform for 3D gastrointestinal endoscopes that will leverage technology for enhanced visualization of blood vessels and lesions as well as AI-assisted detection and characterization applications.
Current fund positioning
In the current market environment, the valuations of our fund investments are at historical lows. This is particularly the case for the Chinese stocks in the portfolios. The average sales growth for the companies in our BB Adamant Asia Pacific Healthcare Fund (LU1587984847) over the next three years is an estimated 20.8%. The fund's average PEG ratio, which is obtained by dividing the P/E ratio by estimated earnings growth, is 1.3. China, the country with the largest weighting in the fund, has a PEG ratio of 0.9 and estimated average sales growth of 37%.
The stocks in the portfolio of the BB Adamant Emerging Markets Healthcare Fund (LU1585228452) are also very attractively valued. The Chinese stocks in this fund's portfolio have an average estimated sales growth of 36% and a PEG ratio of 0.9, while the total portfolio has a PEG ratio of 1.1 with estimated average sales growth of 29.3%. Chinese stocks account for an even higher 59% share of this fund's total investments.
Bellevue Asset Management
Disclaimer: This document is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. It is particularly not intended for US persons, as defined under Regulation S of the U.S. Securities Act of 1933, as amended. The information and data presented in this document are not to be considered as an offer to buy, sell or subscribe to any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient and in particular tax treatment depends on individual circumstances and may be subject to change. This document is not to be relied upon in substitution for the exercise of independent judgment. Before making any investment decision, investors are recommended to ascertain if this investment is suitable for them in the light of their financial knowledge and experience, investment goals and financial situation, or to obtain specific advice from an industry professional. The details and opinions contained in this document are not to be considered as recommendation or investment advice. Every investment involves risk, especially with regard to fluctuations in value and return, and investors' capital may be at risk. If the currency of a financial product is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. Past performance is no indicator for the current or future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs have a negative impact on performance. For more information about the associated costs, please refer to the related costs and fees section of the prospectus. Any benchmarks/indices cited herein are provided for information purposes only. No benchmark/index is directly comparable to the investment objectives, strategy or universe of the subfund. The performance of a benchmark shall not be indicative of past or future performance of the subfund. Financial transactions should only be undertaken after having carefully studied the current valid prospectus and are only valid on the basis of the latest version of the prospectus and available annual and halfyearly reports. Please take note of the risk factors. Countries of distribution and local representatives The Bellevue Funds (Lux) is registered and admitted for public distribution in Austria, Germany, Luxembourg, Spain and Switzerland. Austria Paying and information agent: ERSTE BANK der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna Germany Information agent: ACOLIN Europe GmbH, Reichenaustrasse 11a-c, D-78467 Konstanz Spain Representative: atl Capital, Calle de Montalbán 9, ES-28014 Madrid - CNMV under the number 938 Switzerland The Bellevue Funds (Lux) SICAV is registered for public offering and distribution in Switzerland with the Swiss Financial Market Supervisory Authority. Representative agent in Switzerland: ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich Paying agent in Switzerland: Bank am Bellevue AG, Seestrasse 16, P.O.Box, CH-8700 Küsnacht You can obtain the sales prospectus, Key Investor Information Document ("KIID"), statutes and the current annual and half-yearly reports, the current share prices and further information about the fund free of charge in German from the management company Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht, the representative agent in Switzerland or online at www.bellevue.ch. In respect of the units distributed in or from Switzerland, the place of performance and jurisdiction is at the registered office of the representative agent.
Events im Fokus
1./2. Juni 2022: Fachkonferenz Immobilien & Software | IT
13./14. Juli 2022: Fachkonferenz Beteiligungsgesellschaften & Consumer/Leisure
12./13. Oktober 2022: Fachkonferenz Finanzdienstleistungen/Technologie
Der AKTIONÄR News
26. Mai 06:05 DAX: Rückenwind dank US-Notenbank
26. Mai 06:40 Evonik: Keine Panik
26. Mai 06:53 TSMC: Eigentlich ein klarer Kauf
FY 2021/22 Preliminary Results
02. Juni 2022
Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index
25. Mai 2022